Faculty

Institution

Unit

Venue

Amrita Desai, M.D., M.P.H.

Assistant Professor of Medicine Division of Hematology/Medical Oncology School of Medicine

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Division Of Oncological Sciences

Center For Hematologic Malignancies

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Amrita Desai, M.d., M.p.h. is currently serving as a Biostatistics Shared Resources Assistant Professor of Medicine Division of Hematology/Medical Oncology School of Medicine at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Amrita Desai, M.D., M.P.H.

Oregon Health & Science University

Assistant Professor of Medicine Division of Hematology/Medical Oncology School of Medicine

You can click a keyword to filter the displayed items

medicine hematology oncology immunology cell transplantation bone marrow transplantation lymphoid neoplasia transplantation medicine cellular therapy immunotherapy stem cell transplantation cancer immunotherapy cell therapy cancer care dermatology cancer research leukemia pharmacology clinical research thoracic oncology pharmacotherapy cancer treatment lung cancer surgical oncology hemostasis clinical evidence hematological malignancies cohort studies melanoma cancer immunosurveillance malignant blood disorders clinical outcomes survival analysis laboratory medicine jama oncology clinical case presentation respiratory medicine clinical investigation brain tumor research nuclear cardiology oncogenes cancer discovery disease risk assessment cancer risk disease progression computational medicine computational models clinical radiation oncology case studies clinical case report clinical reviews medical genetics cancer genetics cancer management benchmark studies anti-cancer agents preclinical drug evaluation metronomic therapy full-scale measurement key site multiple scale long-term course risk factors marginal zone lymphoma large cohort single institution higher-grade lymphoma predictive model maintenance rituximab frontline treatment follicular lymphoma frontline brentuximab vedotin short survival frequent transformation brentuximab vedotin caldag-gefi encoding gene pathology clinical transplantation translational research liver transplantation xenotransplantation stem cells transplantation proceeding haematopoiesis cancer letter transplant infectious diseases pediatric transplantation organ transplantation translational medicine

Notable Scholarly Works

Notable Federal Grants

Collaborators

1233 Validation and Clinical Assessment of Bcma and Cd19 Car-T by Dxflex 13-Color Flow Cytometer and Incorporating Immunoregulatory Markers. Laboratory Investigation (2026)

hematologycancer immunotherapycellular therapymedicineimmunophenotypingimmunological biomarkerscell therapyclinical assessmentimmunotherapycancer immunosurveillanceimmunologycell transplantationcd19 car-tincorporating immunoregulatory markersclinical laboratorypathology

Allogeneic Transplant Outcomes in Adults Aged ≥75 Receiving Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

hematologyorgan transplantationmedicineclinical transplantationgraft survivalpost-transplant cyclophosphamideallogeneic transplant outcomesbone marrow transplantationcell transplantationcritical carestem cell transplantationhealth sciencestransplantation medicine

Allogeneic Transplant Outcomes in Patients Aged ≥70 vs 70 With Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

hematologyorgan transplantationmedicineclinical transplantationpost-transplant cyclophosphamidefludarabine/melphalan conditioningallogeneic transplant outcomesbone marrow transplantationcell transplantationcritical carestem cell transplantationtransplantation medicine

Comparative Outcomes of 80 Mg/Kg2 vs 100 Mg/Kg 2 Post-Transplant Cyclophosphamide Following Flumel100 Conditioning in Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy (2026)

hematologymedicineclinical transplantationhaematopoiesiscomparative outcomesbone marrow transplantationmg/kg 2immunologycell transplantationstem cell transplantationtransplantation medicinemg/kg2 vs 100transplantation proceedingclinical trials

Comprehensive Benchmarking of Outcomes After Anakinra Treatment for Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome (Icans). Transplantation and Cellular Therapy (2026)

immune responsesmedicineautoimmune diseasescellular therapyneuroinflammationimmunotoxicologycomprehensive benchmarkingimmunotherapyimmunologyautoimmunityexperimental medicineanakinra treatmentpharmacotherapymedicinal researchtreatment development

Failed Pbsc Mobilization: Combination Dose-Escalated G-Csf + Gm-Csf Successfully Rescues Stem Cell Collection and Allows Autologous Transplantation. Transplantation and Cellular Therapy (2026)

cellular therapymedicinecell therapystem cellsimmunotherapystem cell mobilizationcell transplantationstem cell transplantation

Real-World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (Til) Therapy Program Using Commercial Lifileucel. Transplantation and Cellular Therapy (2026)

hematologymelanoma patientscellular therapymedicinetherapy programoncologyradiation oncologyimmune checkpoint inhibitorscancer carecommercial lifileucelmelanomatumor microenvironment

Real World Outcomes of a Single-Center Tumor Infiltrating Lymphocyte (Til) Melanoma Therapy Program With Commercial Lifileucel.. Transplantation and Cellular Therapy (2026)

melanoma therapy programcancer immunotherapycellular therapymedicineoncologyradiation oncologyimmune checkpoint inhibitorsimmunotherapycancer immunosurveillancecommercial lifileuceljama oncologyreal world outcomesmelanomatumor microenvironmentpathology

hematologymedicineoncologyleukemianeuro-oncologylymphoid neoplasia

339 | Outcomes in an International Multicentre Study of 600 Patients With Cns Relapse of Large B Cell Lymphoma: Compartment of Relapse is Prognostic. Hematological Oncology (2025)

surgical oncologyoncologyradiation oncologyrelapse is prognosticleukemianeuro-oncologymalignant blood disorderslymphoid neoplasiajama oncologypathology

1
2
3
4
5
6
7
10 / page

Amrita Desai, M.D., M.P.H.

Assistant Professor of Medicine Division of Hematology/Medical Oncology School of Medicine

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Division Of Oncological Sciences

Center For Hematologic Malignancies

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Amrita Desai, M.D., M.P.H.

Oregon Health & Science University

Assistant Professor of Medicine Division of Hematology/Medical Oncology School of Medicine

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

1233 Validation and Clinical Assessment of Bcma and Cd19 Car-T by Dxflex 13-Color Flow Cytometer and Incorporating Immunoregulatory Markers. Laboratory Investigation (2026)

Allogeneic Transplant Outcomes in Adults Aged ≥75 Receiving Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

Allogeneic Transplant Outcomes in Patients Aged ≥70 vs 70 With Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

Comprehensive Benchmarking of Outcomes After Anakinra Treatment for Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome (Icans). Transplantation and Cellular Therapy (2026)

Failed Pbsc Mobilization: Combination Dose-Escalated G-Csf + Gm-Csf Successfully Rescues Stem Cell Collection and Allows Autologous Transplantation. Transplantation and Cellular Therapy (2026)

cellular therapymedicinecell therapystem cellsimmunotherapystem cell mobilizationcell transplantationstem cell transplantation

hematologymelanoma patientscellular therapymedicinetherapy programoncologyradiation oncologyimmune checkpoint inhibitorscancer carecommercial lifileucelmelanomatumor microenvironment

Real World Outcomes of a Single-Center Tumor Infiltrating Lymphocyte (Til) Melanoma Therapy Program With Commercial Lifileucel.. Transplantation and Cellular Therapy (2026)

hematologymedicineoncologyleukemianeuro-oncologylymphoid neoplasia

339 | Outcomes in an International Multicentre Study of 600 Patients With Cns Relapse of Large B Cell Lymphoma: Compartment of Relapse is Prognostic. Hematological Oncology (2025)

surgical oncologyoncologyradiation oncologyrelapse is prognosticleukemianeuro-oncologymalignant blood disorderslymphoid neoplasiajama oncologypathology

1
2
3
4
5
6
7
10 / page